Literature DB >> 36161256

Immunoglobulin transmission to infants born to mothers with COVID-19.

Mina Shakery Boroujeni1, Maryam Azizian2, Mahshid Bahrami3, Azin Kheradmand4, Nooshin Tavoosi5, Zeynab Rostamiyan6, Khatereh Forouharnejad7, Sarina Ahmadian6, Iman Naamipouran8, Mehdi Kiaei9.   

Abstract

BACKGROUND: COVID-19 infection is a severe condition in pregnant women. Previous studies have suggested that anti-COVID-19 antibodies may be able to be transmitted from mother to fetus, which in itself is a protective factor in infants against the disease. However, few studies have been done in this area. In the present study, we aimed to investigate the presence of anti-COVID-19 antibodies in infants born to symptomatic and asymptomatic mothers with positive COVID-19 test.
METHODS: This is a cross-sectional study performed in 2021 in Abadan on neonates, born to symptomatic and asymptomatic mothers with positive COVID-19 test. All pregnant women over the age of 38 weeks with positive PCR tests for COVID-19 were included. We collected five cc of blood from the umbilical cord of neonates immediately after birth. The samples were sent to the laboratory in laboratory tubes to measure the anti-COVID-19 IgM and IgG levels.
RESULTS: We evaluated data of 20 neonates born to mothers with symptomatic COVID-19 and 10 neonates born to asymptomatic mothers with positive COVID-19 tests. In symptomatic groups, sixteen neonates (80%) had positive IgG antibodies and the mothers of all these neonates had positive antibodies. The mean IgG levels in infants was 73.26 ± 12.54 RU/ml and the mean IgM levels were 14.29 ± 3.71 RU/ml. Among neonates born to mothers with no symptoms, 7 neonates (70%) had positive IgG antibody. All mothers had positive antibodies. The mean IgG levels in infants were 74.50 ± 11.37 RU/ml and the mean IgM levels was 12.49 ± 2.88 RU/ml. There were no significant differences between two groups of neonates regarding positivity of IgG and antibody levels (P>0.05 for all).
CONCLUSION: 80% of infants born to mothers with COVID-19 pneumonia had positive IgG levels that were in line with the previous reports. IJPPP
Copyright © 2022.

Entities:  

Keywords:  COVID-19; IgG; transmission

Year:  2022        PMID: 36161256      PMCID: PMC9490207     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  21 in total

Review 1.  Alterations in physiology and anatomy during pregnancy.

Authors:  Eng Kien Tan; Eng Loy Tan
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2013-09-04       Impact factor: 5.237

Review 2.  The impact of influenza virus infection in pregnancy.

Authors:  Lucy K Somerville; Kerri Basile; Dominic E Dwyer; Jen Kok
Journal:  Future Microbiol       Date:  2018-01-11       Impact factor: 3.165

Review 3.  COVID-19 pathophysiology: A review.

Authors:  Koichi Yuki; Miho Fujiogi; Sophia Koutsogiannaki
Journal:  Clin Immunol       Date:  2020-04-20       Impact factor: 3.969

4.  Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know.

Authors:  Sonja A Rasmussen; Colleen F Kelley; John P Horton; Denise J Jamieson
Journal:  Obstet Gynecol       Date:  2021-03-01       Impact factor: 7.661

5.  Persistent Symptoms in Patients After Acute COVID-19.

Authors:  Angelo Carfì; Roberto Bernabei; Francesco Landi
Journal:  JAMA       Date:  2020-08-11       Impact factor: 56.272

Review 6.  The SARS-CoV-2 outbreak: What we know.

Authors:  Di Wu; Tiantian Wu; Qun Liu; Zhicong Yang
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

Review 7.  Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.

Authors:  Mark P Lythgoe; Paul Middleton
Journal:  Trends Pharmacol Sci       Date:  2020-04-09       Impact factor: 14.819

Review 8.  Changes in physiology and immune system during pregnancy and coronavirus infection: A review.

Authors:  Miaomiao Chen; Jing Zeng; Xiyao Liu; Guoqiang Sun; Ying Gao; Jiujiang Liao; Jiaxiao Yu; Xin Luo; Hongbo Qi
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2020-10-16       Impact factor: 2.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.